Omeros (OMER) – Business Wire
-
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
-
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
-
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
-
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
-
Omeros Corporation Reports Third Quarter 2023 Financial Results
-
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
-
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thromboti
-
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
-
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
-
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
-
Omeros Corporation Reports Second Quarter 2023 Financial Results
-
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
-
Omeros Announces Webcast Details for Annual Meeting of Shareholders
-
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
-
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
-
Omeros Corporation Reports First Quarter 2023 Financial Results
-
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
-
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
-
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
-
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
-
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
-
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
-
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
-
Omeros Corporation Reports Third Quarter 2022 Financial Results
-
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
-
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
-
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
-
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
-
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
-
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
-
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
-
Omeros Corporation Reports Second Quarter 2022 Financial Results
-
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
-
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
-
Omeros Announces Webcast Details for Annual Meeting of Shareholders
-
Omeros Corporation Reports First Quarter 2022 Financial Results
-
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
-
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
-
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
-
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
-
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
-
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
-
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
-
Omeros Corporation Reports Third Quarter 2021 Financial Results
-
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
-
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
-
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
-
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
-
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
-
Omeros Corporation Reports Second Quarter 2021 Financial Results
Back to OMER Stock Lookup
